The UK Medicines and Healthcare products Regulatory Agency has warned individuals over 60 and those with certain health conditions against receiving a specific Chikungunya vaccine due to safety concerns.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced a significant update on the IXCHIQ Chikungunya vaccine, explicitly advising against its use in individuals aged 60 and over, as well as those with specific health conditions. This directive follows the emergence of global safety data revealing 28 cases of serious adverse reactions linked to the vaccine, including three fatalities. These serious concerns prompted the MHRA to implement restrictions aimed at protecting vulnerable populations.
